{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:13:21Z","timestamp":1772817201806,"version":"3.50.1"},"reference-count":34,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,11,21]],"date-time":"2006-11-21T00:00:00Z","timestamp":1164067200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Musculoskeletal Care"],"published-print":{"date-parts":[[2006,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Background:\u2002Anti\u2010tumour necrosis factor (anti\u2010TNF) therapy has been an important development for the treatment of rheumatoid arthritis (RA) but the impact of its delivery on hospital resources in still emerging.<\/jats:p><jats:p>Aims:\u2002We audited the effect of starting anti\u2010TNF on the use of other anti\u2010rheumatic therapies and hospital resources in a routine secondary care setting.<\/jats:p><jats:p>Methods:\u2002A retrospective study of resource use before and after anti\u2010TNF was conducted. Hospital records of 54 RA patients were studied and data taken from the time of commencing anti\u2010TNF to 1 October 2004 and an equal time period prior to commencing anti\u2010TNF. Identical data were collected for 54 controls not on anti\u2010TNF. Relevant figures were extrapolated to per annum rates. Results were analysed using two\u2010factor ANOVAs comparing the pre\u2010 versus post\u2010anti\u2010TNF period. Cases on intravenous (IV) versus subcutaneous (SC) anti\u2010TNF were also compared in separate ANOVAs.<\/jats:p><jats:p>Results:\u2002Mean duration of anti\u2010TNF therapy was 17.04 months (range 3.60\u201342.36). Mean pre\u2010 and 3\u2010months post\u2010anti\u2010TNF Disease Activity Scores (DAS28) were 6.93 and 3.88, respectively. Cases were more likely than controls to be on oral prednisolone pre\u2010 and post\u2010anti\u2010TNF. Methylprednisolone requirement, number of disease\u2010modifying anti\u2010rheumatic drugs (DMARDs), telephone helpline contacts and duration as an inpatient reduced significantly post\u2010anti\u2010TNF. Day case admissions increased but outpatient appointments decreased only in cases on IV anti\u2010TNF.<\/jats:p><jats:p>Conclusions:\u2002In a pragmatic setting, anti\u2010TNF therapy led to reduced need for steroid injections and other DMARDs, as well as reductions in use of several hospital resources. Wider replication of these findings will be important for planning delivery. Copyright: \u00a9 2006 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/msc.92","type":"journal-article","created":{"date-parts":[[2006,11,21]],"date-time":"2006-11-21T19:33:38Z","timestamp":1164137618000},"page":"204-222","source":"Crossref","is-referenced-by-count":12,"title":["The impact of anti\u2010tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting"],"prefix":"10.1002","volume":"4","author":[{"given":"R. S.","family":"Sandhu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. J.","family":"Treharne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K. M. J.","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Cassim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Saratzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H.","family":"Piper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Erb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tavakoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Deighton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. D.","family":"Kitas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,11,21]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kei127"},{"key":"e_1_2_1_3_1","volume-title":"Standards of Care for Inflammatory Arthritis","author":"Arthritis and Musculoskeletal Alliance","year":"2004"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013961"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21519"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/msc.20"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.6.710"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200010)43:10<2316::AID-ANR20>3.0.CO;2-6"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.7.767"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/msc.2"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kel053"},{"key":"e_1_2_1_12_1","volume-title":"NHS Reference Costs 2003 and National Tariff 2004","author":"Department of Health","year":"2004"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(94)90628-9"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/33.8.765"},{"key":"e_1_2_1_15_1","first-page":"S191","article-title":"Role of biologics in early arthritis","volume":"21","author":"Emery P","year":"2003","journal-title":"Clinical and Experimental Rheumatology"},{"key":"e_1_2_1_16_1","first-page":"1297","article-title":"Costs of rheumatoid arthritis in France: A multicenter study of 1109 patients managed by hospital\u2010based rheumatologists","volume":"31","author":"Guillemin F","year":"2004","journal-title":"Journal of Rheumatology"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.4.341"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh464"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432202"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.017327"},{"key":"e_1_2_1_22_1","unstructured":"2006 Pharmaceutical Press London DK Mehta executive ed) ("},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11439"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707173370301"},{"key":"e_1_2_1_25_1","volume-title":"Technology Appraisal Guidance \u2013 No. 36: Guidance on the Use of Etanercept and Infliximab for the Treatment of Rheumatoid Arthritis","author":"National Institute for Clinical Excellence","year":"2002"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.2165\/00019053-200119100-00006"},{"key":"e_1_2_1_27_1","volume-title":"BSR Statement on Adalimumab for Rheumatoid Arthritis","author":"Palferman T","year":"2003"},{"key":"e_1_2_1_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380107"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/41.7.793"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh441"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.013052"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014340"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.10697"},{"key":"e_1_2_1_34_1","first-page":"i155","article-title":"Patients treated with anti\u2010TNF attending a rheumatology nurse clinic: Response and outcomes of a second or a third anti\u2010TNF switch [abstract","volume":"44","author":"Williams E","year":"2005","journal-title":"Rheumatology"},{"key":"e_1_2_1_35_1","first-page":"S311","article-title":"Cost\u2010effectiveness of 102\u2010weeks of infliximab for rheumatoid arthritis [abstract","volume":"44","author":"Wong JB","year":"2001","journal-title":"Arthritis and Rheumatism"}],"container-title":["Musculoskeletal Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmsc.92","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/msc.92","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T16:37:18Z","timestamp":1700066238000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/msc.92"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11,21]]},"references-count":34,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,12]]}},"alternative-id":["10.1002\/msc.92"],"URL":"https:\/\/doi.org\/10.1002\/msc.92","archive":["Portico"],"relation":{},"ISSN":["1478-2189","1557-0681"],"issn-type":[{"value":"1478-2189","type":"print"},{"value":"1557-0681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,11,21]]}}}